Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | UBE2M | P61081 | 2/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RHOC | P08134 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238740 | 0.86 | UBE2M (0.41) | POLBUBE2MDCUN1D1FPR2ROCK2 | |
| SCHEMBL4236028 | 0.84 | ALDH1A1 (0.47) | UBE2MDCUN1D1MEN1KMT2A | |
| SCHEMBL4240045 | 0.84 | ALDH1A1 (0.47) | UBE2MDCUN1D1MEN1KMT2A | |
| SCHEMBL4239228 | 0.83 | UBE2M (0.45) | UBE2MDCUN1D1RHOCRHOA | |
| SCHEMBL4238870 | 0.82 | MAPT (0.56) | POLBSIGMAR1 | |
| SCHEMBL11457316 | 0.81 | POLB (0.68) | POLBFPR2PROKR1RHOCRHOA | |
| SCHEMBL4247940 | 0.81 | POLB (0.52) | POLBUBE2MDCUN1D1FPR2PROKR1 | |
| SCHEMBL4242742 | 0.80 | UBE2M (0.46) | UBE2MDCUN1D1ROCK2 | |
| SCHEMBL4245557 | 0.80 | UBE2M (0.48) | UBE2MDCUN1D1MEN1KMT2A | |
| SCHEMBL4240447 | 0.80 | POLB (0.35) | POLBSIGMAR1UBE2MDCUN1D1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | POLB 3133/4885SIGMAR1 890/4885UBE2M 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.